Aignostics Launches AI-Powered Application for Tumor Microenvironment Profiling
Aignostics, a pioneering artificial intelligence healthcare company, has recently launched Atlas HE-TME, a revolutionary new application designed for the analysis of tumor microenvironments (TME). This innovative tool aims to address critical challenges in cancer research by providing deep insights from standard hematoxylin and eosin (HE) slides without the need for special staining techniques or multiplexing.
After successfully conducting early-access pilot projects in collaboration with leading biopharmaceutical partners, Aignostics reported the official availability of Atlas HE-TME on October 15, 2025. In just a few hours, researchers can obtain reliable analyses with single-cell resolution across various cancer types. This application allows for a rapid characterization of immune cell populations, spatial relationships, and tissue architectures, enabling scientists to derive significant insights from routinely used HE slides.
Atlas HE-TME was developed using Atlas, the premier basal model created through an alliance between Aignostics, Mayo Clinic, and Charité Berlin. Its powerful analytics engine offers detailed assessments for quality control, encompassing seven different tissue types and nine distinct cell classes, as well as over 5,000 quantitative metrics per image. The application is designed for self-service, and integration with commonly used image management systems is on the horizon. Aignostics has ensured that Atlas HE-TME has been extensively validated across multiple labs and scanner types, ensuring its effectiveness in real-world scenarios. Validation metrics will be available to potential partners upon request.
Dr. Frederick Klauschen, Aignostics' co-founder and Director of the Institute for Pathology at Ludwig Maximilians University in Munich, expressed his enthusiasm, stating, "This is the first time I've seen a model that demonstrates consistently high accuracy across multiple cancer indications with exceptional robustness." Aignostics’ CEO, Viktor Matyas, further emphasized the importance of understanding the TME for the development of effective cancer therapies, noting that traditional approaches can be costly, time-consuming, and limited in scope.
The launch of Atlas HE-TME is seen as a paradigm shift in cancer research methodologies. Pilot projects within the biopharma sector confirmed the application’s ability to deliver high-quality results with unprecedented precision, speed, and breadth, allowing researchers to maximize the value they derive from each HE image.
Atlas HE-TME supports various research applications – from quickly identifying and characterizing tumors with immune infiltration to integrating HE data with spatial transcriptomics for refined analyses of cellular niches. Initially, the application will cater to biopharma partners focusing on breast, bladder, colorectal, liver, and lung cancers. Access for academic institutions is set to roll out in the upcoming months, alongside expanded cancer types and analyses. Interested companies can visit Aignostics' official website for information on free trial opportunities.
Founded in 2020 as a spin-off from Charité Berlin, Aignostics specializes in converting complex pathological data into transformative insights for precision medicine. By combining exclusive access to multimodal clinical data with leading-edge AI technologies and rigorous scientific methods, the company strives to develop premier products and services that support the complete drug development process, from discovery and translational research to clinical trials and companion diagnostics. With a talented team of over 120 employees operating from Berlin and New York, Aignostics is poised to lead innovations in healthcare analytics.
For additional details, visit Aignostics or follow them on LinkedIn at Aignostics LinkedIn.
After successfully conducting early-access pilot projects in collaboration with leading biopharmaceutical partners, Aignostics reported the official availability of Atlas HE-TME on October 15, 2025. In just a few hours, researchers can obtain reliable analyses with single-cell resolution across various cancer types. This application allows for a rapid characterization of immune cell populations, spatial relationships, and tissue architectures, enabling scientists to derive significant insights from routinely used HE slides.
Atlas HE-TME was developed using Atlas, the premier basal model created through an alliance between Aignostics, Mayo Clinic, and Charité Berlin. Its powerful analytics engine offers detailed assessments for quality control, encompassing seven different tissue types and nine distinct cell classes, as well as over 5,000 quantitative metrics per image. The application is designed for self-service, and integration with commonly used image management systems is on the horizon. Aignostics has ensured that Atlas HE-TME has been extensively validated across multiple labs and scanner types, ensuring its effectiveness in real-world scenarios. Validation metrics will be available to potential partners upon request.
Dr. Frederick Klauschen, Aignostics' co-founder and Director of the Institute for Pathology at Ludwig Maximilians University in Munich, expressed his enthusiasm, stating, "This is the first time I've seen a model that demonstrates consistently high accuracy across multiple cancer indications with exceptional robustness." Aignostics’ CEO, Viktor Matyas, further emphasized the importance of understanding the TME for the development of effective cancer therapies, noting that traditional approaches can be costly, time-consuming, and limited in scope.
The launch of Atlas HE-TME is seen as a paradigm shift in cancer research methodologies. Pilot projects within the biopharma sector confirmed the application’s ability to deliver high-quality results with unprecedented precision, speed, and breadth, allowing researchers to maximize the value they derive from each HE image.
Atlas HE-TME supports various research applications – from quickly identifying and characterizing tumors with immune infiltration to integrating HE data with spatial transcriptomics for refined analyses of cellular niches. Initially, the application will cater to biopharma partners focusing on breast, bladder, colorectal, liver, and lung cancers. Access for academic institutions is set to roll out in the upcoming months, alongside expanded cancer types and analyses. Interested companies can visit Aignostics' official website for information on free trial opportunities.
Founded in 2020 as a spin-off from Charité Berlin, Aignostics specializes in converting complex pathological data into transformative insights for precision medicine. By combining exclusive access to multimodal clinical data with leading-edge AI technologies and rigorous scientific methods, the company strives to develop premier products and services that support the complete drug development process, from discovery and translational research to clinical trials and companion diagnostics. With a talented team of over 120 employees operating from Berlin and New York, Aignostics is poised to lead innovations in healthcare analytics.
For additional details, visit Aignostics or follow them on LinkedIn at Aignostics LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.